Capecitabine is an orally administered fluoropyrimidine carbamate which has been developed as a prodrug of 5-FU with the goal to improve its tolerability and intratumoral drug concentration. The review aims to provide an evidence-based update of clinical trials investigating the clinical efficacy, adverse-event profile, dosage and administration of this drug, alone or in combination with conventional chemotherapeutics and/or new target-oriented drugs, in the management of colorectal cancer patients. © 2010 Elsevier Ltd.
Silvestris, N.*, Maiello, E., De Vita, F., Cinieri, S., Santini, D., Russo, A., et al. (2010). Update on capecitabine alone and in combination regimens in colorectal cancer patients. CANCER TREATMENT REVIEWS, 36(SUPPL. 3), S46-S55 [10.1016/S0305-7372(10)70020-7].
Update on capecitabine alone and in combination regimens in colorectal cancer patients
Santini, D.;Russo, A.;
2010-01-01
Abstract
Capecitabine is an orally administered fluoropyrimidine carbamate which has been developed as a prodrug of 5-FU with the goal to improve its tolerability and intratumoral drug concentration. The review aims to provide an evidence-based update of clinical trials investigating the clinical efficacy, adverse-event profile, dosage and administration of this drug, alone or in combination with conventional chemotherapeutics and/or new target-oriented drugs, in the management of colorectal cancer patients. © 2010 Elsevier Ltd.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Update on capecitabine alone and in combination regimens in.pdf
accesso aperto
Dimensione
242.14 kB
Formato
Adobe PDF
|
242.14 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
